Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03734926 | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 90 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT02120911 |
| Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma(TRAP) |
| completed |
| Phase 1 / Phase 2 |
| 40 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER |
| 1 |
| Jul 1, 2020 |
| clinicaltrials |
| NCT02138929 | LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma | completed | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT01102088 | Simultaneous Integrated Boost (SIB) in Esophageal Cancer | completed | Phase 1 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT02964455 | Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 1 | 12 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2020 | clinicaltrials |
| NCT02946671 | Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients | completed | Phase 1 | 16 | Osaka UniversityOTHER | 1 | Mar 6, 2020 | clinicaltrials |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04229537 | Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC | unknown | Phase 1 | 60 | Sinocelltech Ltd.INDUSTRY | 0 | Jan 18, 2020 | clinicaltrials |
| NCT01258868 | Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02347904 | Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer(SOX) | completed | Phase 1 | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02574663 | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | completed | Phase 1 | 66 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT00037817 | Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02843581 | Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02389751 | Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01490749 | Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer | completed | Phase 1 | 17 | Emory UniversityOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT03817567 | Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 50 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 25, 2019 | clinicaltrials |
| NCT01386346 | Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer(VEOX) | completed | Phase 1 | 12 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT03757754 | HPPH Photodynamic Therapy for Patients With Esophageal Cancer(HPPH) | unknown | Phase 1 | 30 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Nov 29, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT03292757 | FLOTOR Pilot Study(FLOTOR) | completed | Phase 1 / Phase 2 | 21 | Oxford University Hospitals NHS TrustOTHER | 1 | Nov 19, 2018 | clinicaltrials |
| NCT03706326 | CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT03213054 | A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer | unknown | Phase 1 | 12 | Oncolys BioPharma IncINDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT01051479 | A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer | completed | Phase 1 | 22 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01561014 | Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02611245 | NIR Fluorescence Imaging Technique in Thoracic Surgery With ICG | completed | Phase 1 | 36 | Chinese Academy of SciencesOTHER_GOV | 1 | Jun 8, 2018 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT01808417 | NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer | completed | Phase 1 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01231399 | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | completed | Phase 1 / Phase 2 | 6 | City of Hope Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT02273713 | The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)(ACTION) | completed | Phase 1 / Phase 2 | 154 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00654160 | Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 7 | Mayo ClinicOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00670553 | A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer | completed | Phase 1 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | May 17, 2017 | clinicaltrials |
| NCT02762474 | Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer | unknown | Phase 1 / Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT03013712 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer(CARTEPC) | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT00524186 | Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer | terminated | Phase 1 | 23 | Roswell Park Cancer InstituteOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT00544362 | Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery | completed | Phase 1 / Phase 2 | 33 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | May 30, 2016 | clinicaltrials |
| NCT02689401 | MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 13, 2016 | clinicaltrials |
| NCT02598687 | Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer. | withdrawn | Phase 1 | 0 | Maastricht Radiation OncologyOTHER | 0 | Apr 21, 2016 | clinicaltrials |
| NCT00701857 | Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer | completed | Phase 1 | 10 | University of ArizonaOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00130936 | Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates | terminated | Phase 1 / Phase 2 | 50 | AHS Cancer Control AlbertaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT02662348 | T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System | unknown | Phase 1 | 6 | Yi MiaoOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT02283359 | Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus | terminated | Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 15, 2016 | clinicaltrials |
| NCT01172028 | Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 33 | University of ArizonaOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00093652 | Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer | terminated | Phase 1 / Phase 2 | — | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jul 24, 2020source: clinicaltrials